Bristol-Myers Squibb (BMS) and Janssen Pharmaceuticals have entered a worldwide alliance to develop and commercialise a Factor XIa (FXIa) inhibitor, BMS-986177, to prevent and treat major thrombotic disorders.
The partners hope to establish a broad development programme for the FXIa inhibitor across various therapeutic indications.
During the second half of this year, the companies intend to advance the investigational anticoagulant agent into Phase II clinical trials for secondary stroke prevention.
BMS executive vice-president and chief scientific officer Tom Lynch said: “We are proud to partner with Janssen on our shared vision for advancing cutting-edge science to develop potential new treatments such as BMS-986177 for serious cardiovascular disease.
“By combining the strength of our companies’ extensive expertise in the development and commercialisation of cardiovascular treatments, we can maximise the potential of FXIa inhibition.”
BMS-986177 is being developed to minimise the risk of vascular events without increasing the risk of bleeding in people with thrombotic conditions.
These conditions include different cardiovascular disorders such as coronary artery disease, strokes and peripheral artery disease.
Janssen research & development global head Mathai Mammen said: “With the addition of a Factor XIa inhibitor programme to our pipeline, Janssen continues to live up to our long-standing commitment of working tirelessly to bring truly transformational therapies to patients worldwide.
“With this new collaboration we have the potential to improve the standard of care for patients with cardiovascular conditions characterised by pathologic thrombosis.”
Janssen will make an undisclosed upfront payment to BMS, which is also eligible for additional milestone payments.
The partners are set to share development costs and commercial profits and losses.